anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators propose to develop and conduct a pilot randomized controlled trial to test a wearable technology-based sedentary behavior (SB) reduction intervention in type 2 diabetes (T2D) patients. The study will recruit 80 participants who will be randomized to either the control group or the intervention group. The 8-week intervention aims to reduce daily SB by at least 120 minutes through the use of Fitbit devices, a smart water bottle, and tailored text messages. Participants will set personalized SB reduction goals and receive prompts to stand or walk, along with hydration reminders from the smart water bottle to encourage movement.

Specifically, the study aims to: determine the acceptability of the SB reduction intervention in T2D patients by evaluating satisfaction and compliance; evaluate the preliminary efficacy of the intervention on reducing total SB time and numbers of prolonged SB bouts; and explore preliminary effects on light physical activity, cardiometabolic markers (24-hour glycemic control, BMI, waist circumference, blood pressure), and patient-centered outcomes (confidence in reducing SB, habit strength for SB, and quality of life). Outcomes will be measured at baseline and post-intervention using biometric assessments, questionnaires, and continuous glucose monitoring. The study seeks to provide insights into the feasibility and potential health benefits of a technology-driven SB reduction program for T2D patients.
Social cognition has become an important treatment target for people with schizophrenia since it has been found to be a strong predictor of functional outcome. Social Cognition and Interaction Training (SCIT) is a manualized, group-based intervention that was developed to address the three core deficits in social cognition associated with severe mental illness: emotion perception, Theory of Mind (ToM), and attributional style. SCIT has demonstrated efficacy in improving social cognition and social functioning in both inpatient and outpatient samples. In addition, evidence also shows that the therapeutic alliance is related to various treatment outcomes. Thus, both the SCIT and a therapeutic alliance focused therapy (TAFT) may both affect social cognition and social function, but through different pathways. TAFT was chosen, as comparison to the SCIT, in order to control for interpersonal relationship variables. In this way, the proposed study will evaluate empirically whether the specific techniques for ameliorating the social cognition of persons with severe mental illness that make-up the SCIT enhance social functioning beyond what is achieved through the effective interpersonal ingredients of the therapeutic alliance. Study purpose: 1) Assess the effectiveness of the SCIT and TAFT interventions, 2) Assess the processes that putatively contribute to the SCIT and TAFT outcomes. Method: A Randomized Controlled Trial (RCT) with one hundred and fifty persons with severe mental illness will be carried out in different psychiatric rehabilitation units and clinics in Israel. To assess the relative effectiveness of the SCIT and TAFT interventions with persons with severe mental illness, both interventions will be compared to treatment as usual (TAU). Clinicians will be trained in both interventions, and outcome measures, including social quality of life and social functioning, as well as mediating processes, including the identification of affective states, ToM, attribution errors and therapeutic alliance, will be assessed. Cognitive functioning and symptom severity will be treated as covariates. Statistical analyses will include analysis of variance which takes into consideration attrition, effect size, mediation processes and covariates.
Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to 450 mg/kg (approximately 19 times the maximum recommended human daily dose (MRHD) in both species when based on body weight; 1.5 times the MRHD in the mouse and 3.3 times the MRHD in the rat when based on body surface area). In mice, the drug was administered for 18 months, whereas in rats, the drug was administered for 18 months followed by an additional 6 months without drug exposure. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females of the 450 mg/kg group. The relevance of this finding to human use is uncertain. Pentoxifylline was devoid of mutagenic activity in various strains of Salmonella (Ames test) and in cultured mammalian cells (unscheduled DNA synthesis test) when tested in the presence and absence of metabolic activation. It was also negative in the in vivo mouse micronucleus test.
This research intended to investigate the influence of the operation of both kinds of hysterectomies in the risk of wound infection and the degree of wound dehiscence. Both of them were open field and laparoscope. In this research, we looked into four databases: PubMed, Web of Science, Embase and Cochrane Library. Research was conducted on various operative methods for hysterectomy in obese patients between 2000 and October 2023. Two independent investigators performed an independent review of the data, established the inclusion and exclusion criteria, and managed the results with Endnote software. It also evaluated the quality of the included literature. Finally, the data were analysed with RevMan 5.3. This study involved 874 cases, 387 cases received laparoscopy and 487 cases received open access operation. Our findings indicate that there is a significant reduction in the rate of post-operative wound infection among those who have received laparoscopy compared with who have received open surgical procedures (odds ratio [OR], 0.04; 95% confidence interval [CI], 0.01-0.15; p < 0.001); There was no statistical difference between the rate of post-operative wound dehiscence and those who received laparotomy compared with those who received open surgical procedures (OR, 0.33; 95% CI, 0.10-1.11; p = 0.07); The estimated amount of blood lost during the operation was less in the laparoscopy group compared with the open procedure (mean difference, -123.72; 95% CI, -215.16 to -32.28; p = 0.008). Generally speaking, the application of laparoscopy to overweight women who have had a hysterectomy results in a reduction in the expected amount of bleeding during surgery and a reduction in the risk of post-operative wound infections.
Lymph node metastases (LNM) is a relatively uncommon but possible complication of T1 esophageal squamous cell carcinoma (ESCC). Existing models do poorly when it comes to quantifying this risk. This study aimed to develop a machine learning model for LNM in patients with T1 esophageal squamous cell carcinoma.

Patients with T1 squamous cell carcinoma treated with surgery between January 2010 and September 2021 from 3 institutions were included in this study. Machine-learning models were developed using data on patients' age and sex, depth of tumor invasion, tumor size, tumor location, macroscopic tumor type, lymphatic and vascular invasion, and histologic grade. Elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble) model of these was generated. Use Area Under Curve (AUC) to evaluate the predictive ability of the model. The contribution to the model of each factor was calculated. In order to better meet clinical needs, the investigators have designed the model as a user-friendly website.
It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin's lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, there has been less research on patients who subsequently develop breakthrough infections. We investigated the effects of the first COVID-19 booster vaccination for patients with B-NHL and the clinical features of breakthrough infections in the Omicron variant era. In this study, B-NHL was classified into two histological subtypes: aggressive lymphoma and indolent lymphoma. Next, patients were subdivided according to treatment with anticancer drugs at the start of the first vaccination. We also examined the clinical characteristics and outcomes of patients who had breakthrough infections after a booster vaccination. The booster effect of the COVID-19 mRNA vaccine in patients with B-NHL varied considerably depending on treatment status at the initial vaccination. In the patient group at more than 1 year after the last anticancer drug treatment, regardless of the histological subtype, the booster effect was comparable to that in the healthy control group. In contrast, the booster effect was significantly poorer in the other patient groups. However, of the 213 patients who received the booster vaccine, 22 patients (10.3%) were infected with COVID-19, and 18 patients (81.8%) had mild disease; these cases included the patients who remained seronegative. Thus, we believe that booster vaccinations may help in reducing the severity of Omicron variant COVID-19 infection in patients with B-NHL.
Nosocomial infections are a major threat to the health sector. A specific category of these are the infections caused by antibiotic induced susceptibility to various pathogenic bacteria. This disclosure relates generally to method and system for combating infections due to antibiotic induced pathogens. The system provides strategies to combat pathogenic infections caused by multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of antibiotic induced pathogens. The idea used in this disclosure utilizes the fact that multiple occurrences of a conserved stretch of nucleotide sequence on a pathogen genome and surrounded by genes encoding virulence factors or which are in vicinity of genes essential for survival of the candidate pathogen can be targeted to disrupt the overall genetic machinery of the pathogen. The present disclosure has been explained on sequenced genomes of  Clostridium difficile  and vancomycin-resistant  Enterococcus sp .
This is a retrospective project. Data will be used from Quality Improvement database for publication purpose. Data was collected from a prospectively collected database that was done as a Quality Improvement Project. The study sites included post anesthesia care units (PACU) of the main and ambulatory campuses of our hospital. The data was collected from surgical and radiology PACU's. Data was collected each quarter for 2 weeks in the surgical PACU, and for 1 month in Radiology PACU, from Sep 2007 through Mar 2012. Trained perioperative nurses and Certified Registered Nurse Anesthesiologist did data collection. This ensured a sample representative of at least 10% of patients anesthetized for surgical and radiological procedures. The independent variables (risk factors) collected included age, American Society of Anesthesiology (ASA) physical status, obesity, preexisting airway or lung disease, preexisting neuromuscular disease or hypotonia, morbid obesity, intraoperative bronchospasm and intraoperative laryngospasm. The primary outcome variables collected were Apnea or hypopnea, Laryngospasm, Bronchospasm, and prolonged Oxygen requirement. Apnea or hypopnea was defined by the need for bag mask ventilation, Laryngospasm by the requirement of a positive pressure ventilation of \> 20 cmH2O or administration of succinylcholine, Bronchospasm by use of albuterol, and Oxygen requirement by continued oxygen administration to maintain SpO2\>92% for 2 hours postoperatively.
Previous studies suggest increased time spent outdoors is associated with lower body mass index (BMI).1,2 . In addition, energy expenditure and hunger have been associated with exposure to heat or cold. Increased usage of central heating and air conditioning systems coupled with increased time spent indoors has created an environment where humans are expending less energy to regulate their body temperature.3 The human thermoneutral zone (TNZ) is the range of ambient temperatures in which a healthy adult can maintain body temperature without expending energy beyond the normal basal metabolic rate. Energy intake and expenditure are adjusted at temperatures above and below the TNZ.4 The temperature of the food, smell, time of consumption, and number of people present are established factors that influence food consumption in humans.5 In addition, evidence supports the role of the environment upon an individual's food intake. Wall color, lighting, and ambient noise, influence consumption preferences and quantities.6 Based on research in animal models, particularly mice and livestock,food intake and subsequently, weight gain is reduced in high ambient temperatures.7-10 In addition in young, physically active, healthy males, food intake is inversely proportional to TNZ.11 However, energy expenditure increases above and below the TNZ. These studies are based on extreme conditions, therefore there is a lack of information on how small changes in ambient temperature may affect food intake in the general human public. Recent research shows the effectiveness of small changes over time to lead to changes in consumption practices.12 Thus, altering the thermal environment subtly may lead to a greater understanding of long term effects in weight management. The investigators have previously examined the thermal environment of persons going about their daily lives in both urban and rural settings (X120217008). Preliminary analysis of the results suggest increased % body fat is associated with lower heat exposure.
The present invention relates to a digestive deglutition type out-of-body electromagnetic excitation positioning system for remotely measuring a capsule, which comprises a three-shaft magnetic field sensor sealed in a capsule, a signal processing module, a wireless communication module, three out-of-body annular coils excited by a magnetostatic field, and a out-of-body data recording instrument which is composed of an SCM control circuit, a constant current source circuit, a multiway switch, a wireless communication module, a memory and a power supply module. When the system works, the three annular coils are fixed on the body surface and orderly provided with exciting current by the data recording instrument to generate a magnetic field. The three-shaft magnetic field sensor in the capsule inside the human body orderly detects the magnetic induction density values of the three coils, and the magnetic induction density values are converted into digital signals by the signal processing circuit and emitted through the wireless communication module. The digital signals are received by the out-of-body data recording instrument and stored in the memory. After the capsule stops working, the position of the capsule at the moment is obtained by the computer according to three field intensity values corresponding to each moment. Thereby, the passing process and the passing time of the capsule in the human body are obtained, and further, the three-dimensional locus of the capsule in the human body is obtained.
NEW MATERIAL:1alpha,24-Dihydroxycholecalciferol monohydrate. USE:Having high calcium absorbing ability from the intestinum tenue, and bone dissolving action, useful as a drug effective for osteopathy of patient of renal insufficiency, hypoparathyroidism, rickets, etc. Crystallized completely, and obtained easily in the form of purity. PROCESS:1alpha,24-Dihydroxycholecalciferol is dissolved in a lower alcohol to give a solution, to which water is added to give crystal of 1alpha,24-dihydroxycholecalciferol monohydrate. Methanol is preferable as the lower alcohol. The amount of the solvent used is preferably 60-80pts.wt. based on 1pt.wt. 1alpha,24-dihydroxycholecalciferol. The amount of water added is preferably 20-80pts.wt. After the addition of water, the solution is fully stirred and allowed to stand at 10-40 deg.C for 1-2 days.
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic liver disease marked by inflammation of the bile ducts and results in the development of strictures and fibrosis. A robust clinical correlation exists between PSC and inflammatory bowel disease (IBD). At present, published data are controversial, and it is yet unclear whether IBD drives or attenuates PSC.
METHODS: Mdr2-deficient mice or DDC-fed mice were used as experimental models for sclerosing cholangitis. Additionally, colitis was induced in mice with experimental sclerosing cholangitis, either through infection with Citrobacter rodentium or by feeding with DSS. Lastly, fibrosis levels were determined through FibroScan analysis in people with PSC and PSC-IBD.
RESULTS: Using two distinct experimental models of colitis and two models of sclerosing cholangitis, we found that colitis does not aggravate liver pathology, but rather reduces liver inflammation and liver fibrosis. Likewise, people with PSC-IBD have decreased liver fibrosis compared to those with PSC alone.
CONCLUSIONS: We found evidence that intestinal inflammation attenuates liver pathology. This study serves as a basis for further research on the pathogenesis of PSC and PSC-IBD, as well as the molecular mechanism responsible for the protective effect of IBD on PSC development. This study could lead to the discovery of novel therapeutic targets for PSC.
The invention discloses albendazole large tablets and a preparation technology thereof. The large albendazole tablets comprise 25wt% of glucosyl beta-cyclodextrin and 41.6wt% of albendazole as well as various auxiliary materials such as starch, apple green, brilliant blue, talcum powder, magnesium stearate and aluminium hydroxide. The preparation technology comprises the following steps of: preparation of starch slurry and a glucosyl beta-cyclodextrin inclusion compound of the albendazole, mixing, pelleting and tabletting. The albendazole large tablets have the advantages that the glucosyl beta-cyclodextrin inclusion compound is used for inclusion of the albendazole so as to improve the slow-release effect and the bioavailability of the albendazole, so that the effective haemoconcentration plasma concentration time of medicines is prolonged, the problem of difficulty in absorption by gastrointestinal tracts is solved, and the pharmaceutical effect is improved; the forming effect of the large tablets is good by the reasonable distribution of the contents of the components in the albendazole large tablets in combination with an inclusion process. The preparation technology is simple and convenient to operate. The albendazole large tablets are used for treating nematodosis in cattle gastrointestinal tracts in clinic, the expelling rate reaches 100%, after the albendazole large tablets are taken for 7 days, the negative conversion ratio and decrement rate of eggs are respectively 86.7% and 98.9%, after 14 days, the negative conversion ratio and the decrement rate reach 100% respectively, and the parasite expelling effect of the albendazole large tablets is obviously superior to those of medicine control groups.
PURPOSE:To produce a specific antibody to a low molecular material by adsorbing or ion-binding the low molecular material onto the surface of metallic colloid to improve the antigenicity of the material then dosing the same to mammals such as rabbit. CONSTITUTION:The low molecular material is adsorbed or ion-bound to the surface of the metallic colloid to improve the antigenicity of the material, then the colloid is dosed to the mammals such as rabbit. The cells having the specified genetic structure to possess the power to produce an antibody, i.e., clones, are thereby produced in the living body of the mammals. Such antibody can be utilized in the form of the antiserum contg. the antibody. The mammals to be dose are mouse, rate or guines pig and are also rabbit, sheep, goat, horse, swine, or bovine. The specific antibody for the low molecular material is thus produced.
Intervention group employs dual-catheter ventricular irrigation, with the lavage catheter placed in the frontal horn of lateral ventricle, and the drainage catheter placed through another burr hole in the ipsilateral occipital horn or in the contralateral ventricle. Lavage is performed twice daily, with each time 500ml of saline over a duration of one hour. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open. Additional treatments, including the administration of antibiotics, are consistent with those in the control group.
The patients received ketorolac in a dose of 90 mg and celecoxib 400 mg orally daily. The drugs were prescribed from the second day of the operation for 5 days.
A composition for bleaching hair is prepared by the admixture of an oxygen liberating substance such as hydrogen peroxide and compounds thereof, and per salts with buffered ammonium salts or buffered salts of organic bases, the oxygen liberating substance being present at least in amount equivalent to 3 per cent by weight of hydrogen peroxide and the solution having a pH of 7 to 9.  Particular oxidizing agents mentioned are hydrogen peroxide, hydrogen peroxide urea, perborates and percarbonates.  The bleaching composition above is preferably used in the presence of high molecular transparent swelling agents such as polysaccharides and albuminous materials. Specified materials are starch tragacanth, methyl cellulose, gum arabic, gelatine, casein, and dextrine.  Wetting agents such as highly sulphonated oils, fatty alcohols, and alcohol sulphonates may also be present.  When dealing with porous hair the composition also contains waxes, lipoids such as lecithin and cholesterin, fatty alcohols, and similar fat materials.  Examples of compositions are: (1) starch, tragacanth, synthetic wax, ammonium chloride, sodium bicarbonate, tertiary sodium phosphate, sodium lauryl sulphonate and hydrogen peroxide; (2) sodium perborate, ammonium chloride, the sodium salt of oleyl-methyl-taurinic acid, potato flour; (3) methyl cellulose, tragacanth, trisodium phosphate, sodium bicarbonate, trimethyl ammonium chloride and hydrogen peroxide urea. Specifications 273,414 and 289,156, [both in Class 91], are referred to.
Hemorrhage, including major hemorrhage defined as symptomatic bleeding in a critical area or organ, can occur with OJEMDA. In the pooled safety population [see Adverse Reactions (6.1)], hemorrhagic events occurred in 37% of patients, including epistaxis in 26% and intratumoral hemorrhage in 9%. Serious events of bleeding occurred in 5% of patients including Grade 5 tumor hemorrhage in 1 patient (0.6%). OJEMDA was permanently discontinued for hemorrhage in 2% of patients. Advise patients and caregivers of the risk of hemorrhage during treatment with OJEMDA. Monitor for signs and symptoms of hemorrhage and evaluate as clinically indicated. Withhold and resume at reduced dose upon improvement, or permanently discontinue based on severity [see Dosage and Administration (2.5)].